ASH Data On CRS Helps Determine Where Anti-CD20 Bispecifics Fit Versus CAR-T
Executive Summary
From the CD20-directed bispecific antibody studies presented at ASH, the risk and severity of cytokine release syndrome is being viewed as a way to determine whether the bispecifics will be used before, after or instead of CAR-Ts.
You may also be interested in...
FDA Nod For Roche’s Columvi Brings Third Anti-CD20 Bispecific To Market
The company is touting the drug’s fixed-duration treatment as an advantage for patients, while the new drug class has ignited discussion around their use in the community oncology setting.
Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space
The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.
Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse
MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.